News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actinium Pharmaceuticals, Inc. (ATNM.OB) Announces Further Development of Actimab-A Manufacturing


4/7/2014 9:47:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A. The new manufacturing process that results in a tenfold improvement of manufacturing yield has been developed by the Company internally in collaboration with IsoTherapeutics. IsoTherapeutics will perform additional experiments to generate documentation necessary for regulatory submissions.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES